UBS Reiterates Buy on Neos Therapeutics (NEOS) - PT to $12

November 11, 2016 9:41 AM EST
Get Alerts NEOS Hot Sheet
Price: $7.45 +7.19%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade NEOS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

UBS maintained a Buy rating on Neos Therapeutics (NASDAQ: NEOS), and cut the price target to $12.00 (from $14.00), following the company's 3Q earnings report. NEOS reported EPS of -$1.61, ahead of estimates of -$1.57.

Analyst Marc Goodman commented, "(1) While revenues were in-line, higher COGS (-$1.4M) offset by lower SG&A (-$0.3M) and R&D (-$1.1M) drove the miss. (2) Adzenys now has access to 83% (70% in 2Q16) of commercial lives. (3) Mgt noted that the Adzenys launch is progressing as planned, and that TRx growth is outperforming other recently launched ADHD medications like QuilliChew ER (Pfizer) and Dyanavel XR (Tris). (4) Both Cotempla and liquid amphetamine XR are on track for submission in 4Q and launch in 2H17. (5) Re S&M, mgt expects 4Q to be below the prior two qtrs, and 2017 to be below 2016. Further, mgt expects 4Q R&D to be higher than 3Q due to PDUFA fees."

For an analyst ratings summary and ratings history on Neos Therapeutics click here. For more ratings news on Neos Therapeutics click here.

Shares of Neos Therapeutics closed at $7.10 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS, Earnings, PDUFA

Add Your Comment